Check 35,000+ stocks against 26 valuation models and 37 quality factors

Lumos Diagnostics Holdings Ltd (LDX) fair value: what the stock is really worth

We calculate from audited financials what Lumos Diagnostics Holdings Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · AU · ISIN AU0000157091

Thin data Jun 24, 2026

Lumos Diagnostics Holdings Ltd

LDX · AU

Weakest SetupStrongly overvalued and low quality.

!Fair value A$0.0255 · Strongly overvalued (−77%)

!Quality 36/100

!Mixed Growth (revenue 5y +16.6 %/yr)

!Loss-making · -75.8% net margin (TTM)

!negative free cash flow

!Trails peers (0/9)

!Narrow moat 12/100

!Insider activity 40/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear A$0.0170 to bull A$0.0340 Growth analysisrevenue history, year by year Quality 36/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Lumos Diagnostics Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range A$0.0100 – A$1.22 · fair‑value band A$0.0170 – A$0.0340 · the A$0.1100 price screens above the A$0.0255 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 24, 2026.

Follow Lumos Diagnostics Holdings in your weekly email

Every Wednesday you see whether Lumos Diagnostics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States.

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Stock analysis

Lumos Diagnostics Holdings Ltd (LDX) currently trades at A$0.1100, while our model-based Fair Value estimate is A$0.0255, implying the stock looks roughly 331.4% overvalued today.

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: A$0.0170 (bear) to A$0.0340 (bull), the price of A$0.1100 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lumos Diagnostics Holdings Ltd reported revenue of $12.5M in FY2024 versus $18.9M in FY2020, a compound −9.8%/yr. Reported net income was −$7.2M in FY2024.

Key figures

Market cap A$92.6M (≈ $65.0M) · P/S ratio 7.58 · EPS (TTM) A$−0.0200 · Net margin −57.5% · Return on equity −123% · Return on assets (EBIT) −33.2% · Operating margin −106% · Revenue (TTM) $12.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −77%, LDX screens richer than that median.

Fair Value models

Bear A$0.0170 Fair Value A$0.0255 Bull A$0.0340

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) n/a n/a A$0.0100 48

All 1 models by family

Asset-Based

NCAV (Graham) n/a n/a A$0.0100 48

Open the full fair value analysis →

Notify me when LDX reaches fair value

Put LDX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 37 · Market factors (momentum, volatility) 23

Profitability 22

Margins and returns on capital today

Quality Growth 66

Are margins and returns improving?

Cashflow 18

Earnings quality: real cash, not paper profit

Fin. Strength 42

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 48

Calm price path (market factor)

Momentum 15

Price trend over the last 3–12 months (market factor)

52W Momentum 8

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+12.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+16.6%

Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+30.7%

’17

’18

’19

’20

’21

’22

’23

’24

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−185.0% (2019) → −62.7% (2024)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss

not computed

LDX screens 331% overvalued. Compare with Abbott Laboratories, →

Compare Lumos Diagnostics Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 363 stocks

Beats the industry median on 0/7 measures

Overall it trails its industry peers.

Valuation

Quality Score 37 · Bottom 25%

Fair Value upside −77% · Bottom 25%

Profitability

Return on assets −29% · Bottom 25%

Net margin (TTM) −76% · Bottom 25%

Operating margin (TTM) −106% · Bottom 25%

Growth and dividend

Revenue growth −3% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 10.56× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (TTM) 5.32× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$101.07	$74.79	−26%
Medtronic plc MDT	$88.64	$65.61	−26%
Stryker Corporation SYK	$269.75	$296.73	+10%
Boston Scientific Corporation BSX	$43.92	$48.31	+10%
Edwards Lifesciences Corporation EW	$86.29	$81.94	−5%
Siemens Healthineers AG SHL	€37.79	€35.19	−7%
DexCom, Inc DXCM	$86.62	$95.28	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lumos Diagnostics Holdings Ltd · Fair Value
A$0.0255 −331%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/LDX" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Lumos Diagnostics Holdings Ltd · Fair Value</span><br><b style="font-size:20px">A$0.0255</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−331%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Lumos Diagnostics Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/LDX

Frequently asked questions

Is Lumos Diagnostics Holdings Ltd (LDX) overvalued or undervalued?

As of Jun 24, 2026, our model estimates a fair value of A$0.0255 versus a price of A$0.1100, about −77% upside (overvalued).

What is the fair value of LDX?

Our model-based fair value for Lumos Diagnostics Holdings Ltd is A$0.0255 (as of Jun 24, 2026), built from audited fundamentals. The current price: A$0.1100.

What is the quality score of LDX?

Lumos Diagnostics Holdings Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Lumos Diagnostics Holdings Ltd (LDX)?

Our model-based price target is the fair value of A$0.0255 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario A$0.0170, optimistic scenario A$0.0340. It is a calculation from audited fundamentals, not an analyst target.

What is the Lumos Diagnostics Holdings Ltd stock forecast for 2026?

Our models put fair value at A$0.0255, about −77% upside versus a price of A$0.1100 (overvalued). Cautious scenario A$0.0170, optimistic scenario A$0.0340. The calculation is refreshed regularly with new filings.

What is the revenue of Lumos Diagnostics Holdings Ltd (LDX)?

Lumos Diagnostics Holdings Ltd reported trailing-twelve-month revenue of about $12.2M (latest available figure, as of Jun 24, 2026).

What is the intrinsic value of Lumos Diagnostics Holdings Ltd (LDX)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lumos Diagnostics Holdings Ltd it is A$0.0255 per share (as of Jun 24, 2026), against a price of A$0.1100. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Lumos Diagnostics Holdings Ltd stock overvalued or undervalued in 2026?

As of Jun 24, 2026, LDX trades above its calculated fair value: price A$0.1100, fair value A$0.0255, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of LDX?

No. The price is what the market pays today (A$0.1100); the fair value is what the company's own numbers justify (A$0.0255). For Lumos Diagnostics Holdings Ltd the two are A$0.0845 per share apart. That gap is exactly why we show both numbers side by side.

How much is Lumos Diagnostics Holdings Ltd worth?

The market values Lumos Diagnostics Holdings Ltd at about A$92.6M (market capitalisation, as of Jun 24, 2026). Per share that is A$0.1100; our models calculate a fair value of A$0.0255 per share.

What do the bullish and bearish scenarios say about LDX?

Our models span a range for Lumos Diagnostics Holdings Ltd: cautious scenario A$0.0170, base A$0.0255, optimistic A$0.0340 per share (as of Jun 24, 2026, price A$0.1100). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Lumos Diagnostics Holdings Ltd (LDX)?

Balance-sheet figures for Lumos Diagnostics Holdings Ltd (as of Jun 24, 2026): return on equity −123.3%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.

How far is LDX from its 52-week high?

Lumos Diagnostics Holdings Ltd trades at A$0.1100, about 66% below its 52-week high of A$0.3200 and 38% above the low of A$0.0800 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0255 is for.

Which stocks are comparable to Lumos Diagnostics Holdings Ltd?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Lumos Diagnostics Holdings Ltd stock attractive at the current price?

The data as of Jun 24, 2026: price A$0.1100, calculated fair value A$0.0255 (−77%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of LDX calculated?

We run Lumos Diagnostics Holdings Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0255, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.2 % above its aggregate fair value. Lumos Diagnostics Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Lumos Diagnostics Holdings Ltd (LDX)?

The closing price on Sep 25, 2026 was A$0.1100. Our model-based fair value is A$0.0255, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Lumos Diagnostics Holdings Ltd right now?

The price sits above even our optimistic bull case (A$0.0340). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.0170 to A$0.0340) leaves room in how you read the outcome.

Key figures of Lumos Diagnostics Holdings Ltd

How large is the market capitalisation of Lumos Diagnostics Holdings Ltd (LDX)?

The market capitalisation of Lumos Diagnostics Holdings Ltd is A$92.6M (≈ $65.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Lumos Diagnostics Holdings Ltd (LDX)?

The price-to-sales ratio of Lumos Diagnostics Holdings Ltd is 7.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Lumos Diagnostics Holdings Ltd (LDX)?

Earnings per share at Lumos Diagnostics Holdings Ltd are A$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Lumos Diagnostics Holdings Ltd (LDX)?

The net margin of Lumos Diagnostics Holdings Ltd is −57.5% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Lumos Diagnostics Holdings Ltd (LDX)?

The return on equity (ROE) of Lumos Diagnostics Holdings Ltd is −123% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Lumos Diagnostics Holdings Ltd (LDX)?

On an EBIT basis the return on assets of Lumos Diagnostics Holdings Ltd is −33.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Lumos Diagnostics Holdings Ltd (LDX)?

The operating margin of Lumos Diagnostics Holdings Ltd is −106% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Lumos Diagnostics Holdings Ltd (LDX)?

Revenue at Lumos Diagnostics Holdings Ltd is growing −3.0% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Lumos Diagnostics Holdings Ltd (LDX) generate?

The free cash flow of Lumos Diagnostics Holdings Ltd is −$9.4M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Lumos Diagnostics Holdings Ltd (LDX) carry?

The net debt of Lumos Diagnostics Holdings Ltd is $5.0M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Lumos Diagnostics Holdings Ltd in the live analysis

One click puts Lumos Diagnostics Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.